// App-Quantinova.ai

4506 : A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).

Researchers

Presenter

  • Simon Chowdhury

Principal Investigators

  • David F. McDermott

  • Martin Henner Voss

  • Robert E. Hawkins

  • Paola Aimone

  • Maurizio Voi

  • Naeije Isabelle

  • Yi Wu

  • Jeffrey R. Infante

Medical Centers

  • Sarah Cannon Research Institute, London, United Kingdom

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Novartis Pharmaceuticals AG, Basel, Switzerland

  • Novartis Oncology, East Hanover, NJ

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Cancer antigen 15-3

  • Programmed cell death protein 1

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

  • Pazopanib

Outcome

  • Unknown

Study Design

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved